China XLX Fertiliser
2021 Interim Results Highlights:
- Achieved revenue of approximately RMB 7,573 million, rising by 53% Y-O-Y.
- Revenue derived from the sales of urea increased by 32% Y-O-Y to approximately RMB2,074 million. Gross profit margin of urea increased to approximately 35.4% from approximately 26.8% last year.
- The unaudited total comprehensive income attributable to the owners of the parent increased significantly by 259% to approximately RMB646 million for 1H2021. Earnings per share reached 55.1 RMB cents in 1H2021.
HONG KONG / ACCESSWIRE / August 9, 2021 / China XLX Fertiliser Ltd. ("China XLX" or the "Company", together with its subsidiaries collectively known as the "Group") (HKSE:01866.HK) announced the interim results o for the six months ended 30 June 2021 (the "Period"). The Group recorded a revenue of approximately RMB7,573 million, increased by 53% from the same period last year. Gross profit increased sharply by 99.4% to approximately RMB2,118 million. Profit for the period surged by 237% to approximately RMB 889 million from last year. The comprehensive income attributable to owners of the parent company jumped by 259% to approximately RMB646 million, as compared with the same time last year.
In the first half of 2021, the recovery of the domestic fertilisers and chemical products market has accelerated. With the Group's third production base in Jiangxi Jiujiang successfully commissioned in February 2021, total production capacity reached new height, further solidifying geographical coverage, forming Central, Northwest and Southeast three strategic production bases in the PRC.
With the Jiujiang production base put into production, the market share of the Group has increased and its cost advantage has been further enhanced. Additionally, the rising global food price and increasing demand further boosted the sales of key products of the Group, contributing to satisfying results for 1H2021. Revenue derived from the sales of urea increased by 32% to approximately RMB2,074 million. The leap was mainly due to the increase in sales volume and the average selling price of urea products of the Group by approximately 8% and 23% Y-O-Y, respectively. Gross profit margin of urea of the Group increased to approximately 35.4% for 1H2021 from approximately 26.8% for 1H2020.
Strong results have also been recorded in the businesses of compound fertilisers and methanol. Revenue derived from the sales of compound fertilisers increased by 13% to approximately RMB1,981 million for 1H2021, mainly due to the increase in sales volume and average selling price of compound fertilisers by approximately 5% and 8% respectively. Revenue derived from the sales of methanol was up by 355% to approximately RMB733 million for 1H2021. The increased sales of methanol were a result of the increase in average selling price and sales volume of methanol of the Group by 57% and 190% YoY respectively. The increased sales volume was mainly contributed by the additional production capacity of the third production base in Jiujiang. Due to the rebound in international energy prices which in turn boosted the average selling price of methanol, gross profit margin of methanol of the Group rose by approximately 22 percentage points to approximately 19.7% for 1H2021.
Revenue derived from the sales of Dimethyl Ether (DME) rose by 79% to approximately RMB618 million for 1H2021. Revenue derived from the sales of melamine increased largely by 69% to approximately RMB535 million for 1H2021. Revenue derived from the sales of furfuryl alcohol products was up by 48% to approximately RMB335 million for 1H2021. The revenue from the sales of urea solution for vehicle reached approximately RMB236 million for 1H2021, due to product structure adjustment.
Looking ahead, Mr. Liu Xingxu, Chairman of China XLX, said that with the introduction of the new agricultural reform policies and the "dual-carbon" policies, the acceleration of elimination of the backward production capacity and emphasis on the high-quality and efficient green development of the agriculture industry would be beneficial to the development of industry leaders. The Group adheres to the strategy of green, low carbon and sustainable development in terms of production, R&D or product innovation, which will provide favourable conditions for consolidating the main fertilisers industry. In addition, the chemical product market is affected by rising international energy prices, strong downstream demand, and the business cycle of chemical product prices will continue at a high level. Each of the Group's chemical product can meet the various needs of its downstream users. On the basis of consolidating the competitive advantages of our existing chemical products, the Group would be committed to extending the development of the industrial chain. As new products continue to be put into production, it will definitely further enhance the Group's profitability and market competitiveness.
Since the Jiujiang production base has been put into production, the market share of the Group has increased and its cost advantage has been further enhanced. The Group will leverage its three major production bases to strengthen its competitive advantage of "low-cost and differentiation" and widen its business horizon. Being committed to leading the industry as "Pioneer of High-Efficiency Fertilisers in China" to lead the industry with higher standard and support the industry's continuous exploration in high efficiency fertiliser and scientific agriculture, the Group strives to reward farmers and serve the community with higher standards, and to make higher contribution to China agriculture.
~END~
About China XLX Fertiliser Ltd.
China XLX Fertiliser Ltd. is one of the largest and most cost-efficient coal-based urea producers in China. The Group is principally engaged in developing, manufacturing, and selling of related differentiated products such as urea, compound fertiliser, methanol, dimethyl ether, melamine, furfuryl alcohol, furfural, 2-methylfuran and pharmaceutical intermediates. Adhering to the competitive strategy of combination of "comprehensive cost control and product differentiation", the Group aims at further development of the fertiliser industry as a whole. Boasting resources of its Henan, Xinjiang, Jiujiang bases, the Group strives to expand its business into various upstream product lines including new energy, new chemical materials, and coal chemicals. The Group is committed to becoming the most respected enterprise in the chemical fertilisers industry. The Company's shares are traded on the main board of the Stock Exchange of Hong Kong Limited (stock code: 01866.HK).
Investor and Media Enquiries
China XLX Fertiliser Ltd.
GUI, Lin
Tel: 86-135 6942 3415
Email: lin.gui@chinaxlx.com.hk
PRChina Limited
Joanne Liu/ Jack Liu/ Rachel Xia
Tel: 852-2522 1368 / 852-2522 1838
Email: jjyliu@prchina.com.hk
zyliu@prchina.com.hk
rxia@prchina.com.hk
SOURCE: China XLX Fertiliser
View source version on accesswire.com:
https://www.accesswire.com/658898/China-XLX-Announces-2021-Interim-Results-Strong-and-Solid-Recovery-with-NP-Surging-by-259
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK tes Launches New Circular IT Facility in Shannon, Expanding Ireland’s Role in Global Sustainable Tech Services24.4.2025 09:30:00 CEST | Press release
SHANNON, IE / ACCESS Newswire / April 24, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, has announced plans to open a new 36,000 square foot purpose-built facility in Shannon, marking a major vote of confidence in Ireland's thriving data and technology sector. The new facility will deliver comprehensive ITAD, data center decommissioning, and technology lifecycle management services to some of Ireland's largest enterprises, including hyperscale data center operators, while supporting national sustainability and circular economy goals. It will also create over 25 skilled jobs in one of the country's fastest-growing tech regions. "Ireland is at the forefront of Europe's digital economy, and our investment in Shannon reinforces our commitment to helping Irish companies manage technology securely, sustainably, and at scale," said Eric Ingebretsen, Chief Commercial Officer at SK tes. "This facility will allow us to meet the uniqu
Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release
Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release
Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom